Table 8.
First author | Year | Number of patients | Stage | Factor | Correlation |
Giatromanolaki 6 | 1997 | 134 | I, II | CD31 | NS |
Pastorino 8 | 1997 | 137 | I | CD31 | NS |
Fontanini 9 | 1997 | 407 | I–III | CD34 | S |
Duarte 26 | 1998 | 106 | I | VIII, CD31 | S, NS |
Imoto 27 | 1998 | 91 | I–III | VEGF | S |
Matsuyama 11 | 1998 | 101 | I–III | CD34 | S |
Decaussin 12 | 1999 | 81 | I, II | VEGF | NS |
Kakolyris 13 | 1999 | 69 | I, II | CD31 | S |
Yano 5 | 2000 | 108 | I–IV | CD34, VEGF | S, NS |
Koukourakis 10 | 2001 | 102 | I, II | VEGF | S |
Han 14 | 2001 | 85 | I | VEGF | S |
Offersen 7 | 2001 | 143 | I–III | VEGF, CD34 | NS, NS |
Tanaka 15 | 2001 | 236 | I–III | CD105, CD34 | S, NS |
NS, not significant; NSCLC, non-small cell lung cancer; S, significant; VEGF, vascular endothelial growth factor.